Future directions in imaging prostate cancer

Michael J. Manyak, John H Makari

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

All of these advances suggest that rapid coregistration of images from a variety of sources will be possible to compile a very detailed composite about an individual tumor biology. Coregistration superimposes radiographic images to further define specific anatomic areas of interest. As currently used in treatment planning and dosimetric assessment for radiotherapy, coregistration of computed tomography (CT) and MRI has shown superiority over use of pelvic bony reference marks.7 The addition of functional imaging to anatomic information from CT and ultrasound is now being utilized for intraprostatic dose escalation strategies and for confirmation of 3D energy delivery.8 This combination of functional and anatomic imaging with MRI and MR spectroscopic imaging (MRSI) to provide high-resolution spatiovascular information in prostate cancer is also under review.9,10 Furthermore, coregistration of radiolabeled monoclonal antibody scans with both CT and MRI have improved specificity for both newlydiagnosed prostate cancer and recurrent disease.11,12 Established clinical applications of gray-scale TRUS in prostate cancer include biopsy guidance, placement of radioactive seeds, and assessment of response to therapy. Despite the advantages of a relatively inexpensive, fast, and minimally invasive imaging technology, TRUS has shown very limited benefit for detection and staging of prostate cancer and is not recommended for screening. It has a relatively low sensitivity and specificity because most hypoechoic peripheral zone lesions are not malignant, and up to 56% of carcinomas are isoechoic.13 Likewise, TRUS is not very sensitive for detection of seminal vesicle invasion and is more suited as a guide for biopsy in those cases suspected of seminal vesicle involvement.14.

Original languageEnglish (US)
Title of host publicationProstate Cancer
Subtitle of host publicationPrinciples and Practice
PublisherCRC Press
Pages543-549
Number of pages7
ISBN (Electronic)9780203624326
ISBN (Print)9781841844589
StatePublished - Jan 1 2005
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Seminal Vesicles
Tomography
Biopsy
Seeds
Radiotherapy
Monoclonal Antibodies
Technology
Carcinoma
Sensitivity and Specificity
Direction compound
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Manyak, M. J., & Makari, J. H. (2005). Future directions in imaging prostate cancer. In Prostate Cancer: Principles and Practice (pp. 543-549). CRC Press.

Future directions in imaging prostate cancer. / Manyak, Michael J.; Makari, John H.

Prostate Cancer: Principles and Practice. CRC Press, 2005. p. 543-549.

Research output: Chapter in Book/Report/Conference proceedingChapter

Manyak, MJ & Makari, JH 2005, Future directions in imaging prostate cancer. in Prostate Cancer: Principles and Practice. CRC Press, pp. 543-549.
Manyak MJ, Makari JH. Future directions in imaging prostate cancer. In Prostate Cancer: Principles and Practice. CRC Press. 2005. p. 543-549
Manyak, Michael J. ; Makari, John H. / Future directions in imaging prostate cancer. Prostate Cancer: Principles and Practice. CRC Press, 2005. pp. 543-549
@inbook{74407178340b4e1ca8cc75fbe9e35dfe,
title = "Future directions in imaging prostate cancer",
abstract = "All of these advances suggest that rapid coregistration of images from a variety of sources will be possible to compile a very detailed composite about an individual tumor biology. Coregistration superimposes radiographic images to further define specific anatomic areas of interest. As currently used in treatment planning and dosimetric assessment for radiotherapy, coregistration of computed tomography (CT) and MRI has shown superiority over use of pelvic bony reference marks.7 The addition of functional imaging to anatomic information from CT and ultrasound is now being utilized for intraprostatic dose escalation strategies and for confirmation of 3D energy delivery.8 This combination of functional and anatomic imaging with MRI and MR spectroscopic imaging (MRSI) to provide high-resolution spatiovascular information in prostate cancer is also under review.9,10 Furthermore, coregistration of radiolabeled monoclonal antibody scans with both CT and MRI have improved specificity for both newlydiagnosed prostate cancer and recurrent disease.11,12 Established clinical applications of gray-scale TRUS in prostate cancer include biopsy guidance, placement of radioactive seeds, and assessment of response to therapy. Despite the advantages of a relatively inexpensive, fast, and minimally invasive imaging technology, TRUS has shown very limited benefit for detection and staging of prostate cancer and is not recommended for screening. It has a relatively low sensitivity and specificity because most hypoechoic peripheral zone lesions are not malignant, and up to 56{\%} of carcinomas are isoechoic.13 Likewise, TRUS is not very sensitive for detection of seminal vesicle invasion and is more suited as a guide for biopsy in those cases suspected of seminal vesicle involvement.14.",
author = "Manyak, {Michael J.} and Makari, {John H}",
year = "2005",
month = "1",
day = "1",
language = "English (US)",
isbn = "9781841844589",
pages = "543--549",
booktitle = "Prostate Cancer",
publisher = "CRC Press",

}

TY - CHAP

T1 - Future directions in imaging prostate cancer

AU - Manyak, Michael J.

AU - Makari, John H

PY - 2005/1/1

Y1 - 2005/1/1

N2 - All of these advances suggest that rapid coregistration of images from a variety of sources will be possible to compile a very detailed composite about an individual tumor biology. Coregistration superimposes radiographic images to further define specific anatomic areas of interest. As currently used in treatment planning and dosimetric assessment for radiotherapy, coregistration of computed tomography (CT) and MRI has shown superiority over use of pelvic bony reference marks.7 The addition of functional imaging to anatomic information from CT and ultrasound is now being utilized for intraprostatic dose escalation strategies and for confirmation of 3D energy delivery.8 This combination of functional and anatomic imaging with MRI and MR spectroscopic imaging (MRSI) to provide high-resolution spatiovascular information in prostate cancer is also under review.9,10 Furthermore, coregistration of radiolabeled monoclonal antibody scans with both CT and MRI have improved specificity for both newlydiagnosed prostate cancer and recurrent disease.11,12 Established clinical applications of gray-scale TRUS in prostate cancer include biopsy guidance, placement of radioactive seeds, and assessment of response to therapy. Despite the advantages of a relatively inexpensive, fast, and minimally invasive imaging technology, TRUS has shown very limited benefit for detection and staging of prostate cancer and is not recommended for screening. It has a relatively low sensitivity and specificity because most hypoechoic peripheral zone lesions are not malignant, and up to 56% of carcinomas are isoechoic.13 Likewise, TRUS is not very sensitive for detection of seminal vesicle invasion and is more suited as a guide for biopsy in those cases suspected of seminal vesicle involvement.14.

AB - All of these advances suggest that rapid coregistration of images from a variety of sources will be possible to compile a very detailed composite about an individual tumor biology. Coregistration superimposes radiographic images to further define specific anatomic areas of interest. As currently used in treatment planning and dosimetric assessment for radiotherapy, coregistration of computed tomography (CT) and MRI has shown superiority over use of pelvic bony reference marks.7 The addition of functional imaging to anatomic information from CT and ultrasound is now being utilized for intraprostatic dose escalation strategies and for confirmation of 3D energy delivery.8 This combination of functional and anatomic imaging with MRI and MR spectroscopic imaging (MRSI) to provide high-resolution spatiovascular information in prostate cancer is also under review.9,10 Furthermore, coregistration of radiolabeled monoclonal antibody scans with both CT and MRI have improved specificity for both newlydiagnosed prostate cancer and recurrent disease.11,12 Established clinical applications of gray-scale TRUS in prostate cancer include biopsy guidance, placement of radioactive seeds, and assessment of response to therapy. Despite the advantages of a relatively inexpensive, fast, and minimally invasive imaging technology, TRUS has shown very limited benefit for detection and staging of prostate cancer and is not recommended for screening. It has a relatively low sensitivity and specificity because most hypoechoic peripheral zone lesions are not malignant, and up to 56% of carcinomas are isoechoic.13 Likewise, TRUS is not very sensitive for detection of seminal vesicle invasion and is more suited as a guide for biopsy in those cases suspected of seminal vesicle involvement.14.

UR - http://www.scopus.com/inward/record.url?scp=85056680189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056680189&partnerID=8YFLogxK

M3 - Chapter

SN - 9781841844589

SP - 543

EP - 549

BT - Prostate Cancer

PB - CRC Press

ER -